Reply from the authors

Abstract

We thank Dr. Blasi et al. for their comments on our paper. 1 Below are our responses to their comments.We found that a short-term administration of antithrombin III (AT-III) reduces portal vein thrombosis (PVT) more significantly (in 20 of 36 patients, 55.6%) than does placebo (in 7 of 36 patients, 19.4%). Although Dr. Blasi pointed out that our administration of the trial drugs was short, the ideal length of anticoagulation ther-Response to Annabel Blasi's Letter to the Editor Comment to "Antithrombin III administration for portal vein thrombosis in patients with liver disease: A randomized double-blind controlled trial"